Recent research into the pathophysiology of MDD is revealing novel treatment targets that go beyond monoamines and include other targets, such as glutamate neurotransmission (e.g. ketamine and other modulators); modulation of cholinergic and gamma-aminobutyric acid (GABA)-ergic transmission; neuronal plasticity; stress/hypothalamic pituitary adrenal (HPA)-axis; neuroinflammation; and the reward system via modulation of opioid receptors and beta endorphins. In this session, Dr. Maletic will compare the safety and efficacy of novel MDD agents and their complementary role within the current treatment armamentarium.
Supported by an educational grant from Alkermes, Inc.
